Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer.

Front Immunol · 2021 · PMC8039370 · PMID 33854509

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

A phase II trial that combined MoDC vaccine with docetaxel showed a trend toward improvement in disease specific survival (DSS) ( 46 ), and results of the first phase III trial, NCT NCT02111577 that combines docetaxel and DC vaccine therapy are eagerly awaited.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.